Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Database
Language
Affiliation country
Publication year range
1.
Mutat Res ; 506-507: 121-7, 2002 Sep 30.
Article in English | MEDLINE | ID: mdl-12351151

ABSTRACT

There is growing interest in the potential health benefits of tea, and a recent report described the potent antimutagenic activity of white tea in comparison with green tea against several heterocyclic amines, including 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) [Mutat. Res. 495 (2001) 61]. We compared the inhibitory effects of white and green teas with sulindac, a nonsteroidal anti-inflammatory agent, in two different mouse models of intestinal tumorigenesis. In the Apc(min) mouse, white and green teas given at human-relevant concentrations (1.5% w/v, 2-min brew), and sulindac (80 ppm in the drinking water), each suppressed polyp formation by approximately 50%, and the combination of white tea plus sulindac was more effective than either treatment alone (P=0.05). Mice expressing an N-terminally truncated, oncogenic version of beta-catenin (A 33(delta N beta-cat) mutant mice) developed colonic aberrant crypt foci (ACF) spontaneously, but PhIP treatment increased the incidence and number of ACF per colon. In the normal-looking intestinal mucosa of Apc(min) and A 33(delta N beta-cat) mice, white tea plus sulindac treatment markedly attenuated the expression of beta-catenin protein, and this was recapitulated in vitro in cells transiently transfected with beta-catenin plus Tcf-4 and treated with tea or the major tea polyphenol epigallocatechin-3-gallate (EGCG). Expression of a beta-catenin/Tcf reporter was inhibited by EGCG in the transfected cells, and the beta-catenin/Tcf target genes cyclin D1 and c-jun were downregulated in vivo by tea plus sulindac treatment. Collectively, the data support a chemopreventive role for tea and sulindac against intermediate and late stages of colon cancer, via effects on the beta-catenin/Tcf signaling pathway.


Subject(s)
Adenomatous Polyposis Coli Protein/metabolism , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Catechin/analogs & derivatives , Intestinal Neoplasms/prevention & control , Plant Extracts/pharmacology , Polyps/prevention & control , Sulindac/pharmacology , Tea , Adenomatous Polyposis Coli Protein/deficiency , Adenomatous Polyposis Coli Protein/genetics , Animals , Catechin/pharmacology , Cell Line , Cytoskeletal Proteins/deficiency , Cytoskeletal Proteins/genetics , Cytoskeletal Proteins/metabolism , Drug Combinations , Imidazoles/toxicity , Intestinal Mucosa/drug effects , Intestinal Mucosa/metabolism , Intestinal Neoplasms/chemically induced , Intestinal Neoplasms/metabolism , Luciferases/metabolism , Male , Mice , Mice, Inbred C57BL , Mice, Mutant Strains , Polyps/chemically induced , Polyps/metabolism , Trans-Activators/deficiency , Trans-Activators/genetics , Trans-Activators/metabolism , beta Catenin
SELECTION OF CITATIONS
SEARCH DETAIL